AccuBase™: The Cutting-Edge Base Editing Enzyme Driving Breakthroughs of NK Cell Cancer Therapy

KACTUS, the strategic partner of Base Therapeutics, is the exclusive supplier of GMP-grade AccuBase™, the world’s first “off-the-shelf” cytosine base editor and the key raw material for clinical manufacturing of NK510 cell injection, an allogenic, universal NK cell injection developed by Base Therapeutics via its independent base editing technology. As of July 29th, 2024, the Center of Drug Evaluation (CDE) has formally accepted the IND application of NK510 Cell Injection, primarily targeting solid tumors in advanced stages. This marks a significant milestone in cancer therapy, showcasing the potential of NK510's as an"off-the-shelf" NK cell product

The successful application of AccuBase™ in NK510 production indicates the immersive potential of GMP-grade base editors in CGT manufacturing. Meanwhile, it also demonstrates KACTUS’ strong  manufacturing  capability of  GMP-grade enzymes with complex structures and delicate functions. 

AccuBase™: The Game-Changer in Gene Editing

AccuBase™ is the world’s first, and currently the only, protein-based cytosine base editor (CBE) on the market. It was independently developed by Base Therapeutics with exclusive global IP rights. The AccuBase™ product line can precisely convert cytosine (C) to thymine (T) with nearly zero off-target effects. This high-efficiency, precise base editing capability has been validated across various cell types, making it an invaluable tool in gene editing.

Key Features of AccuBase™:

• High-Efficiency Base Editing Activity: AccuBase™ effectively knocked out PD1, B2M, and TRAC proteins in primary T cells, with knockout efficiencies exceeding 80% and up to 96% in certain cases.

• Near-Zero Off Target Efficiency: Genome-wide off target analysis demonstrated that AccuBase™ achieves off-target levels comparable to control groups, making it an extremely precise tool for gene editing.

• No INDELs or Chromosomal Translocations: In contrast to Cas9 protein, AccuBase™ does not cause insertions and deletions (INDELs) or chromosomal translocations, enhancing the safety profile of gene editing applications.

 

In  NK510, the GMP-grade AccuBase ™ enabled high-precision gene editing of NK cells, with an overall efficiency of more than 90% enhancing their ability to overcome cancer cell immune evasion, while still maintaining the effective target and killing cancer cells with an efficiency exceeding 90%. By allowing precise C-to-T conversions without causing DNA double-strand breaks, AccuBase™ ensures minimal off-target effects, enhancing the safety and effectiveness of NK510. 

Manufacturing and Global Supply of AccuBase™ by KACTUS

By leveraging the exclusive  Structure Aided Design and Multiplex Screening SAMS™ platform, KACTUS has successfully developed the process to stably produce the AccuBase ™ with high stability, high purity, and high activity. The manufacturing of  AccuBase™ is conducted in strict compliance with GMP standards, meeting the requirements of  IND and BLA filing. Currently, KACTUS was granted, by Base Therapeutics,  with the exclusive rights of manufacturing and global sales of the AccuBase™ around the world.

Right now,  KACTUS offers cost-effective, off-the-shelf  Research-Grade and GMP-grade AccuBase™, both of which are globally in stock and ready to ship to the end user on next day, aiming to fulfill the unmet needs in current gene editing therapy research, development and manufacturing. 

About Base Therapeutics

Base Therapeutics was founded in April 2021, specializing in the research and development of novel gene-editing NK cell therapy and gene therapy products. They have developed the patented AccuBase base editing system, which has global Freedom To Operate (FTO) and can achieve highly efficient gene editing both in vitro and in vivo with zero off-target effects. In addition, they have developed ePE, a highly efficient prime-editing technology. Based on these proprietary foundational technologies, Base Therapeutics focuses on developing First-in-Class BED-NK and BEAT-CAR-T product pipelines, as well as multiple in vivo base editing product lines. 

About KACTUS

KACTUS is an innovation-driven company specializing in recombinant proteins and enzyme raw materials, dedicated to serving the development and production of biopharmaceuticals. Since its establishment in 2018, KACTUS has accumulated rich experience in protein R&D and production through its unique structure-designed protein development platform SAMS ™. KACTUS has built its own GMP facility and certified quality system, providing various GMP-grade raw proteins and enzymes to meet the needs of cell and gene therapy drug development. Several GMP-grade products have completed FDA DMF filings.